Maxygen, Inc. (Nasdaq:MAXY) today announced that it has been advised by
the Biomedical Advanced Research and Development Authority (BARDA) that
Maxygen’s proposal for the development of its MAXY-G34 product candidate
...

Maxygen, Inc. (Nasdaq:MAXY), a biotechnology company, today announced
that the United States Patent and Trademark Office (PTO) has issued a
Right of Appeal Notice in the inter partes reexamination proceeding for
...

Maxygen, Inc. (Nasdaq:MAXY), a biopharmaceutical company focused on
developing improved versions of protein drugs through both internal
development and external collaborations and other arrangements, today
announced...

Maxygen, Inc. (Nasdaq:MAXY) today announced that it has submitted a
proposal to the Biomedical Advanced Research and Development Authority
(BARDA) for a multi-year, multi-million dollar contract for the
development of...

Shares of Maxygen (Nasdaq:MAXY) have taken a tremendous swing upward. The stock is trading at $5.30 as of 9:32 a.m. ET, 28.9% above Wednesday's closing price of $4.11. Volume is at 262,647, two times the daily average of 134,500.

Maxygen, Inc. (Nasdaq:MAXY), a biopharmaceutical company focused on
developing improved versions of protein drugs through both internal
development and external collaborations and other arrangements, today
announced...